Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Aug 17, 2026
Why Is AirSculpt Technologies (AIRS) Stock Down -11.37% Today?

Why Is AirSculpt Technologies (AIRS) Stock Down -11.37% Today?

Key Takeaways

  • Shares of AIRS fell 11.37% to $3.04 in Monday trading, down $0.39 from Friday’s close of $3.43.
  • The decline extends post-earnings turbulence following the company’s August 10 second-quarter report.
  • Q2 revenue of $42.9 million missed consensus and fell 3% year over year; the full-year adjusted EBITDA outlook was cut to $12–$14 million.
  • No fresh company-specific announcement was apparent during Monday’s slide, pointing to technical and sentiment-driven selling.
  • Traders are watching the $3.00 area and upcoming Q3 case-volume and margin trends.

Opening Summary

AirSculpt Technologies, Inc. (AIRS) is a provider of minimally invasive body contouring procedures in the United States and Canada. In Monday afternoon trading, shares dropped 11.37% to $3.04, compared with Friday’s close of $3.43. The decline extended a period of elevated volatility that began when the company reported second-quarter results on August 10, and the market’s immediate focus remained on the weaker profitability outlook rather than on any new corporate announcement.

Q2 Results and Lowered Profit Outlook

The primary overhang on AIRS remains the second-quarter report released before the market open on August 10. Revenue came in at $42.9 million, down 3% from $44.0 million a year earlier and below the consensus estimate of roughly $44.2 million. Net loss widened to $1.1 million from $0.6 million in the prior-year period, while adjusted EBITDA declined to $4.9 million from $5.8 million.

Management reaffirmed full-year revenue guidance but said results are expected to track toward the lower end of the $151 million-to-$157 million range. More importantly for investor sentiment, the company reduced its full-year adjusted EBITDA guidance to $12 million-to-$14 million. That downward revision to profitability expectations has kept selling pressure on the stock even after the initial post-earnings reaction.

Technical Selling and Post-Earnings Volatility

The stock’s recent path illustrates how volatile AIRS has become. The shares closed at $5.01 on August 7, then collapsed to $2.75 on August 10 after the earnings release. A partial recovery followed over the next four sessions, lifting the stock back to $3.43 by August 14. Monday’s slide to $3.04 unwound most of that rebound in a single session.

With a beta near 2.4 and a relatively small float, AIRS is prone to outsized intraday moves. The absence of a fresh company-specific catalyst during Monday’s decline suggests that the move was driven by continued digestion of the lowered earnings outlook, profit-taking after last week’s bounce, and momentum-driven selling once the shares surrendered key short-term support.

Market Context and Trading Activity

Turnover in AIRS has been elevated relative to early-August levels since the earnings report. Daily volume surged to roughly 2.5 million shares on August 10 and remained well above the early-August baseline in subsequent sessions, reflecting intense two-way trading as investors repositioned.

The selling on Monday appeared largely company-specific rather than tied to a broad market catalyst. The stock’s slide below the $3.30 level and toward $3.00 placed it back near the lower end of its recent post-earnings range, a technical breakdown that likely contributed to additional selling pressure during the afternoon.

What Comes Next for AIRS

Investors will be watching whether AIRS can stabilize above the $3.00 level or whether the post-earnings range continues to compress. The next scheduled quarterly report is expected in November, and management commentary on same-center case volumes, revenue per case, and adjusted EBITDA margins will be central to the investment debate.

Additional focus areas include the rollout of newer procedures such as skin tightening and skin removal, the planned AlloClae pilot, demand trends among GLP-1 patients, and progress on debt refinancing. Consumer spending on elective cosmetic procedures remains a key macroeconomic risk, and the company’s ability to convert higher marketing investment into sustained case growth will likely determine whether the recent volatility gives way to a more durable trend.

Trending AI Robots

Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in its curated Trending AI Robots section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing traders to explore automated approaches tailored to different market environments. Investors seeking a data-driven way to monitor opportunities across active tickers may find the section a useful starting point.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AIRS

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


AIRS sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for AIRS moved below the 200-day moving average on September 29, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AIRS as a result. In 61 of 71 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AIRS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for AIRS entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for AIRS just turned positive on October 05, 2026. Looking at past instances where AIRS's MACD turned positive, the stock continued to rise in 35 of 42 cases over the following month. The odds of a continued upward trend are 83%.

Following a +12.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where AIRS advanced for three days, in 231 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

AIRS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.293) is normal, around the industry mean (208.195). P/E Ratio (196.563) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.921) is also within normal values, averaging (2.688).

The Tickeron Price Growth Rating for this company is 93 (best 1 - 100 worst), indicating slightly worse than average price growth. AIRS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AIRS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock worse than average.

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 4.84B. The market cap for tickers in the group ranges from 20.9K to 93.66B. HCA holds the highest valuation in this group at 93.66B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was 0%. For the same Industry, the average monthly price growth was -8%, and the average quarterly price growth was 17%. BMGL experienced the highest price growth at 16%, while NIVF experienced the biggest fall at -51%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was -49%. For the same stocks of the Industry, the average monthly volume growth was 0% and the average quarterly volume growth was -30%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 45
Price Growth Rating: 53
SMR Rating: 66
Profit Risk Rating: 87
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
AIRS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry HospitalNursingManagement

Industry
N/A
Address
1111 Lincoln Road
Phone
+1 786 709-9690
Employees
453
Web
https://www.airsculpt.com
Interact to see
Advertisement
The Bitwise Solana Staking ETF (BSOL) advanced roughly 18% over the trailing 30 days, closely tracking a sharp rally in Solana (SOL). The move extends a broader recovery, with BSOL up approximately 77% over the past three months from its mid-2026 trough.
MSTY is an actively managed single-stock option income ETF (exchange-traded fund) that writes call options on Strategy (MSTR), formerly MicroStrategy, to generate current income. The portfolio is anchored by U.S. Treasury bills and MSTR option contracts rather than a diversified basket of equities, concentrating exposure in one volatile underlying.
AMDL has surged roughly +64% over the past 30 days, from about $47.59 to $78.10, mirroring a powerful rally in its sole underlying stock, AMD . The fund is a leveraged single-stock ETF (exchange-traded fund) designed to deliver 2x the daily return of AMD, amplifying both gains and losses.
TSMX, a 2x daily leveraged single-stock ETF (exchange-traded fund), rose roughly +19% over the trailing 30 days, rebounding sharply from mid-September lows. The fund seeks 200% of the daily return of TSM (Taiwan Semiconductor Manufacturing), meaning its moves are roughly double the underlying stock's daily swings.
Contracted revenue anchor: A roughly $3.2 billion, seven-year LNG (liquefied natural gas) supply agreement with Puerto Rico has received final approval, providing multi-year cash-flow visibility if execution stays on track. Project pipeline inflection: Upcoming milestones include the Barcarena and PortoCem power plants in Brazil, a potential Gás Sul terminal restart, and optimization of the company's modular "Fast LNG" (FLNG) liquefaction fleet.
AMD (Advanced Micro Devices) designs central processing units (CPUs), graphics processing units (GPUs), and AI accelerators, while LRCX (Lam Research) supplies the wafer-fabrication equipment used to build advanced chips. AMD has delivered strong double-digit revenue growth on AI data-center demand, but its shares trade with elevated expectations that can trigger sharp reactions around earnings.
Origination momentum: Velocity Financial enters 2026 off record annual originations of roughly $2.7 billion (up about 48%), positioning it to keep gaining share in a fragmented investor-loan market. Credit normalization is the central watch item: Nonperforming loans fell toward the 8.5% range of portfolio unpaid principal balance (UPB), but asset quality remains the primary swing factor for earnings.
Turnaround milestone ahead: Management has pointed to reaching cash generation in 2027, making the pace of cost discipline and margin recovery the central question for the stock forecast. Fresh capital supports execution: A recently announced $45.5 million equity financing, with participation from management and a single institutional investor, strengthens the balance sheet as the company funds its transformation.
NFE closed at $5.51, down -6.13% during Tuesday's regular session, extending a slide that has pushed shares near a 52-week low. Primary catalyst: the company disclosed its Fast LNG unit is offline after a gas-turbine mechanical failure, with return to service not expected until Q4.
The central $11 target is the arithmetic mean of four verified analyst price targets, rounded from roughly $10.75. With the stock near $2.06, reaching $11 would require an upside of more than 400%, an extremely large move.
The $23 central target is the rounded arithmetic mean of four verified analyst price targets, which average $23.25. The latest verified price is around $9.57, meaning the target implies roughly 140% upside—a very large move.
NXH closed down -11.17% (-$0.23) to $1.83 on Oct 6, the most recent regular session, extending a steep two-day decline. Selling continued as investors digested the mutual termination of the Fathom Holdings merger and a dilutive $45.5M registered direct offering of ~16.5M shares at $2.76.
AMD is a large-cap designer of CPUs (central processing units) and GPUs (graphics processing units) competing directly with Nvidia in the AI accelerator market, while FORM is a small-cap provider of semiconductor test and measurement equipment, primarily probe cards. AMD's narrative has been driven by multi-billion-dollar hyperscaler deals, while FORM's has been powered by record revenue and sharp margin expansion tied to high-bandwidth memory (HBM) demand.
AMD has surged roughly 200% year to date, crossing a $1 trillion market capitalization on AI data-center demand and a "CPU renaissance" narrative. KLAC has gained about 71% year to date, supported by record process-control revenue and rapid growth in advanced packaging for AI chips.
AMD is a large-cap semiconductor designer riding explosive AI compute demand, while ENTG is a mid-cap supplier of materials and purity solutions that feed the same AI-driven chip cycle. AMD recently crossed a $1 trillion market capitalization on surging data center revenue, whereas ENTG operates at a far smaller scale (roughly $23 billion) with steadier, double-digit growth.
VELO closed Tuesday at $9.57, unchanged (+0.00%) from the prior session, with the move occurring during regular market hours. The flat close marked stabilization after Monday's -14.5% plunge, when shares fell to $9.57 from $11.20 following disclosure of CFO James Suva's departure.
The $8 target used here is a technical, publicly discussed recovery objective — not an analyst consensus — because legacy analyst price targets were set before NFE's restructuring and reverse stock split. New Fortress Energy Inc. ( NFE ) trades near $5.51, so reaching $8 implies a roughly 45% advance.
AVBP plunged -46.98% during Tuesday's regular session, closing at $15.09 versus $28.46, marking its worst single-day decline on record. The catalyst was the Phase 3 FURVENT trial of firmonertinib failing its primary endpoint—progression-free survival—in first-line EGFR exon 20 insertion non-small cell lung cancer.
Upcoming catalyst: The company's next earnings release is estimated for November 6, 2026, which should offer fresh detail on its SKY token holdings, staking rewards, and treasury strategy. Strategic positioning: SDEV is an on-chain holding company providing public-market exposure to the Sky protocol ecosystem, with SKY as its core digital asset and a stated focus on the stablecoin economy.
Different roles in the chip ecosystem: AMAT is a materials-engineering and deposition leader, while KLAC dominates process control, inspection, and yield management. Momentum favors AMAT: AMAT shares have more than doubled this year, while KLAC has recently pulled back roughly 9% in a month on margin and execution concerns.